...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>AIDS Research and Human Retroviruses >A report on the effect of commencing enfuvirtide on peripheral neuropathy.
【24h】

A report on the effect of commencing enfuvirtide on peripheral neuropathy.

机译：关于开始恩夫韦肽治疗周围神经病变的报道。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Enfuvirtide is the first fusion inhibitor approved for use in HIV treatment and is a useful therapeutic option for highly treatment experienced individuals. Passive reporting has associated increased neuropathy rates with enfuvirtide use in some early studies but not others. The aim of this study was to describe any functional or clinical changes consistent with neuropathy among enfuvirtide users. A prospective cohort study of patients commencing or continuing enfuvirtide at a state HIV referral service, including clinical and sensory threshold monitoring, was conducted. A total of 14 patients were studied. All had advanced HIV disease and 13 (93%) had symptoms and/or signs consistent with neuropathy at baseline. Patients who entered the study on enfuvirtide-based therapy remained neurologically stable throughout follow-up. Eleven patients were assessed preand postenfuvirtide. No evidence was found for any clear effect of enfuvirtide on neuropathic symptoms, neuropathic signs, or sensory thresholds at a cohort level (p > 0.3 for all, Wilcoxon signed rank test). However, three (21%) patients experienced worsening of existing neuropathy symptoms (transient in two cases) and two (14%) patients' symptoms improved with enfuvirtide commencement. Breakthrough HIV viremia was associated with worsening symptoms in two patients at 5 and 18 months of enfuvirtide use. This study found no clear effect on peripheral nerves from enfuvirtide. Although limited by a small sample size, this study involved patients who would have been particularly vulnerable to a neurotoxin, with advanced HIV disease and a high rate of baseline neurological abnormalities. We observed no clear evidence of neurotoxicity from enfuvirtide in this population.
机译：Enfuvirtide是第一种被批准用于HIV治疗的融合抑制剂，对于经验丰富的个体是有用的治疗选择。在一些早期研究中，被动报告已将神经病发生率与恩夫韦肽的使用相关联，而在其他研究中却没有。这项研究的目的是描述与恩夫韦肽使用者的神经病变相符的任何功能或临床变化。对在国家艾滋病毒转诊服务中开始或继续使用恩夫韦肽的患者进行了一项前瞻性队列研究，包括临床和感官阈值监测。共研究了14例患者。所有患者均患有晚期HIV疾病，其中13例（93％）的症状和/或体征与基线时的神经病变相符。参加基于恩夫韦肽治疗的研究的患者在整个随访过程中均保持神经学稳定。十一名患者接受恩夫韦特前后治疗。在队列研究水平上，未发现恩夫韦肽对神经性症状，神经性体征或感觉阈有任何明显作用的证据（所有p> 0.3，Wilcoxon符号秩检验）。但是，三名（21％）患者的现有神经病症状恶化（两例为短暂性），两名（14％）患者的症状随恩夫韦肽治疗而改善。在使用恩夫韦肽5个月和18个月时，突破性的HIV病毒血症与两名患者症状恶化有关。这项研究发现恩夫韦肽对周围神经没有明显作用。尽管受样本量的限制，但这项研究的患者本来就特别容易受到神经毒素的影响，患有晚期HIV疾病和较高的基线神经系统异常率。我们在该人群中未观察到恩夫韦肽对神经毒性的明确证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号